Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Surgically Resected Pancreatic Cancer

NCT01072981 is registered in ClinicalTrials.gov with NewLink Genetics Corporation as lead sponsor.

NCT NCT01072981
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01072981 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Surgically Resected Pancreatic Cancer
Lead sponsor
NewLink Genetics Corporation
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2010
Completion date
May 31, 2016
Enrollment
722 (actual)
Sites
75

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer